NEXALIN TECHNOLOGY INC (NXL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.06-5.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · NXL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 267.7% |
| Our one-year growth estimate | diamond | -26.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 294.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
NXL — legal / regulatory event — Notice of Delisting or Failure
Dated 2026-08-17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 14, 2026, Nexalin Technology, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $1,519,423 reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the mini…
Why it matters: This partnership could mean growth for Nexalin Technology.
Supportive ifA press release about new projects with GreenLight Ventures.
Worry ifNo news or delays in the partnership this quarter.
Why it matters: Fixing the Nasdaq listing issue is key for keeping investor trust.
Supportive ifNexalin meets Nasdaq listing rules by getting a bid price above $1.00.
Worry ifNexalin does not fix the Nasdaq listing issue and risks delisting.
Why it matters: The reverse stock split is crucial for maintaining Nasdaq listing. If it fails, the stock may be delisted.
Worry ifNexalin's stock price remains above $1.00 per share for at least 30 consecutive trading days after August 31, 2026.
Less concerning ifNexalin's stock price falls below $1.00 per share again within 30 trading days after the split.
Why it matters: Trial results will indicate the product's potential and impact on future sales.
Supportive ifNews of good trial results or meeting key goals.
Worry ifNegative trial results or failure to meet primary endpoints.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$367 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $1,103 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,093 loss on $10,000 · 90.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Integrating PONM well is key for HALO Clarity's success in clinics and sales.
Supportive ifNexalin says it will integrate PONM's AI into HALO Clarity by Q3 2026.
Worry ifThere are integration problems. This delays using PONM's platform in the HALO Clarity trial.
Why it matters: Updates on this partnership may show better skills and help Nexalin's product growth.
Supportive ifNexalin says the partnership with GreenLight helps their clinical and business plans.
Worry ifThere are no updates or bad news about how the partnership affects Nexalin's work.
Why it matters: The FDA's choice on the De Novo submission will affect HALO Clarity's market entry.
Supportive ifNexalin has FDA clearance for the HALO Clarity device. They used the De Novo pathway.
Worry ifThe FDA denies the De Novo submission or asks for more data, delaying approval.
Why it matters: Enrollment in the pivotal trial is key for Nexalin's FDA submission and future product launch.
Supportive ifEnrollment of at least 160 participants begins as planned in Q2 2026.
Worry ifEnrollment is delayed or fewer than 160 participants are enrolled by the end of Q2 2026.